-
The company had multiple rounds of position cuts through 2022 and 2023 at its Bloomington facility and at others across the country.
-
Novo Nordisk along with Sanofi and Indianapolis-based Eli Lilly control over 90 percent of the world insulin market.
-
Current and former Catalent board members have been accused of short-handing production regulations and providing inaccurate information about the company’s business and financial status.
-
IU President Pamela Whitten keynoted the State of the Bloomington Regional Economy meeting Wednesday, which was hosted by the Bloomington Economic Development Corporation.
-
Did the army corps of engineers may have left graves unexhumed when they flooded Lake Monroe? What will happen to Catalent's tax abatement since it laid off 150 employees? And why is Bloomington covered in smoke? These stories and more on Indiana Newsdesk.
-
After multiple rounds of job cuts in the last year, Catalent is not likely to receive the abatement granted to it by the city of Bloomington in 2022.
-
The email sent to employees Wednesday said the company’s growth during the pandemic is not sustainable, and the layoffs are the result of restructuring.
-
Bloomington was mentioned specifically in a press statement by the company for failing to meet expected production, which Catalent attributed to required enhancements after inspections earlier this year.
-
The money is available through the Regional Economic Acceleration and Development Initiative program - a state program launched by Gov. Eric Holcomb meant to increase economic opportunity in Indiana.
-
Rapid growth during the pandemic factored into both Catalent’s plans and expectations of the City of Bloomington. But cutbacks began this summer when Catalent laid off 204 temporary workers.